Regional variation of cytosol androgen receptors throughout the diseased human prostate gland.
The heterogeneous histology of the normal and diseased human prostate is well established. This study has investigated variations in cytosol androgen receptor (AR) content throughout the diseased gland to establish the most suitable sites to obtain tissue for AR assay. Only then can AR be investigated as a potential predictor of response to endocrine treatment. In a transverse slice of an enucleated prostate showing benign prostatic hyperplasia (BPH) AR levels in 1-g segments varied from 109 to 1,212 fmol/g tissue (mean 483 +/- 273; median 406), with no negative areas. Areas of higher receptor concentrations corresponded to the glandular regions of sections obtained from a slice taken in juxtaposition; areas of low receptor concentrations corresponded to the stromal regions. A significant correlation (P less than .02) was observed between AR concentration and the proportion of glandular components of each segment. Specimens were also obtained from each of three sites from 38 prostates; 45% of all specimens contained AR; however, distribution of receptor throughout the prostate was uneven. AR were significantly more likely to be measured in the peripheral zone (71% positive) than in periurethral tissue (39% positive) whilst only 24% of specimens taken from the limit of the resection possessed AR binding capacity. Similar distribution patterns were observed in both benign and malignant prostates, although 16% more specimens from carcinomatous prostates contained receptor than did those from benign glands; this difference was maintained at each site. In addition receptor levels were consistently lower in benign than in malignant specimens. It is therefore desirable to know the histological composition of specimens used for AR measurement.
Bowman
S P
SP
Barnes
D M
DM
Blacklock
N J
NJ
Sullivan
P J
PJ
D003600:Cytosol / Q000032:analysis; D004963:Estrenes / Q000378:metabolism; D006801:Humans; D008297:Male; D015741:Metribolone; D011467:Prostate / Q000032:analysis* / Q000473:pathology; D011470:Prostatic Hyperplasia / Q000473:pathology*; D011471:Prostatic Neoplasms / Q000032:analysis / Q000473:pathology*; D011944:Receptors, Androgen / Q000032:analysis* / Q000378:metabolism; D011960:Receptors, Estrogen / Q000032:analysis; D045165:Testosterone Congeners / Q000378:metabolism; D014316:Tritium
D004963:Estrenes; D011944:Receptors, Androgen; D011960:Receptors, Estrogen; D045165:Testosterone Congeners; D014316:Tritium; D015741:Metribolone